Fast-track analysis for first-line treatment

Frequently, a very rapid decision for a first-line treatment is necessary after the diagnosis of lung cancer. To bring our philosophy of a comprehensive, best possible molecular diagnostics into line with the need for rapid decision-making for a potential molecular therapy, since early 2015, and in addition to the comprehensive diagnostics by multiplex PCR or hybrid capture sequencing, we carry out a so-called Fast-Track Analysis for individual parameters which are very important for the first-line treatment (EGFR, ALK, KRAS, possibly also ROS1). Requesting physician are provided with these parameters within 4 working days in advance.
Netzwerk Genomische Medizin (NGM) Lungenkrebs

Last update: 07. March 2016 , 12:04

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Diagnostics
w

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Second Opinion
n

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.

Trials